Therapeutic Category:Central nervous system drugs
Pharmacologic Category:Cerebral Vasodilator
Tablets, Injection (Ampoule)
Cavintine improves cerebral perfusion hereby improving the oxygen supply of the brain.
In vivo experiments show that it enhances cerebral regeneration after experimental hypoxia.
For the management of psychic and neurological symptoms (memory disorders, aphasia, apraxia, motor disorders, dizziness, headache) of cerebral circulatory disorders of various origin (postapoplectic, posttraumatic or sclerotic).
- Hypertensive encephalopathy.
- Intermittent vascular cerebral insufficiency.
- Angiospastic states.
- Cerebral endarterisis.
- Cavintine improves collateral circulation in:
- Ischaemic cerebral injuries.
- Advanced cerebral arteriosclerosis.
- Vascular arteriosclerosis of the retina and chorioid.
- Secondary glaucoma due to partial thrombosis or vascular occlusion.
- Vascular or toxic audio deficiency.
- Vertigo of labyrinth origin.
In neurology, in acute focal ishaemic cerebrovascular conditions where haemorrhagic origin can be absorlutely excluded.
Pregnancy and lactation, severe ischaemic heart diseases, severe arrhythmias.
With parenteral treatment the blood sugar level of diabetic patients should be checked because of the sorbitol content of the ampoule .
5. SIDE EFFECTS:
Slight hypotension, tachycardia, immature beats may occur occasionally.
On long-term treatment blood count is suggested to be performed.
No interactions of the tablets with other drugs were reported, therefore it can be administered in combination.
The injection is incompatible with heparin therefore it can not be injected to patients on heparin therapy.
7. DOSAGE & ADMINISTRATION:
Oral: 3 times 1- 2 tablets.
Maintenance Dose: 1 tablet 3 times daily, for a longer period of time.
Parenteral: Initial daily dose is 20 mg in slow drip infusion (2 ampoules in 500-1000 ml infusion solution).
Later on the usual daily dose is 30 mg (3 ampoules in 500 –1000 ml infusion solution) in slow drip infusion.
If necessary, and the patients tolerates it the daily infused total dose can be raised carefully reaching 1 mg/kg body-weight on day 10.
Intravenous and intramuscular dosage should be avoided.
8. PACKAGING & COMPOSITION:
CAVINTINE - Tablets: A pack of 20 tablets. Each tablet contains Vinpocetine 5 mg.
CAVINTINE 10 – Injection: A pack of 5 ampoules of 2 ml. Each ampoule (2ml) contains Vinpocetine 10 mg.
Store CAVINTINE - Tablets at temperatures below 25 ° C.